Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Osimertinib for Residual Ground-glass Opacity Nodules after Curative Resection in EGFR-positive Lung Adenocarcinoma
KCT0007721Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of osimertinib in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by AstraZeneca. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on KCT0007721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007721.